SLC5A2 and kidney disorder: Recent findings from the DAPA-CKD and EMPA-KIDNEY trials have revealed that SGLT-2 inhibitors offer significant benefits in improving cardiovascular and renal function, as well as delaying the progression of renal disease in stage G4 DKD patients, irrespective of their diabetes status (9, 10).